Gastroenterology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gastroenterology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Dana-Farber Cancer Institute
Researchers exploit genetic 'co-dependence' to kill treatment-resistant tumor cells
November 2nd, 2009
BOSTON and CAMBRIDGE--Cancer cells fueled by the mutant KRAS oncogene, which makes them notoriously difficult to treat, can be killed by blocking a more vulnerable genetic partner of KRAS, report scientists at the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT. The laboratory results, published by Nature on its Web site as an advanced online publication and later in a print edition, demonstrate a potential advance against many major tumors which, because they harbor the mutant KRAS cancer gene, are highly aggressive and respond poorly to treatment. By targeting the second, more easily inhibited "co-dependent" gene, TBK, the strategy bypasses the...
Source: Gastroenterology Week (2009-11-02)
|
